


Please cite the Published Version

Hájek, Milan, Flögel, Ulrich, S. Tavares, Adriana A., Nichelli, Lucia, Kennerley, Aneurin J , Kahn, Thomas, Futterer, Jurgen J., Firsiori, Aikaterini, Grüll, Holger, Saha, Nandita, Couñago, Felipe, Aydogan, Dogu Baran, Caligiuri, Maria Eugenia, Faber, Cornelius, Bell, Laura C., Figueiredo, Patrícia, Vilanova, Joan C., Santini, Francesco, Mekle, Ralf and Waiczies, Sonia (2024) MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention. *Magnetic Resonance Materials in Physics, Biology and Medicine*, 37 (3). pp. 323-328. ISSN 1352-8661

DOI: <https://doi.org/10.1007/s10334-024-01176-5>

Publisher: Springer

Version: Published Version

Downloaded from: <https://e-space.mmu.ac.uk/635748/>

Usage rights:  [Creative Commons: Attribution 4.0](https://creativecommons.org/licenses/by/4.0/)

Additional Information: The version of record of this article, first published in *Magnetic Resonance Materials in Physics, Biology and Medicine*, is available online at Publisher's website: <http://dx.doi.org/10.1007/s10334-024-01176-5>

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)



MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention

Milan Hájek¹ · Ulrich Flögel² · Adriana A. S. Tavares³ · Lucia Nichelli^{4,5} · Aneurin Kennerley^{6,7} · Thomas Kahn⁸ · Jurgen J. Futterer⁹ · Aikaterini Firsiori¹⁰ · Holger Grüll^{11,12} · Nandita Saha^{13,14} · Felipe Couñago¹⁶ · Dogu Baran Aydoğan¹⁷ · Maria Eugenia Caligiuri¹⁸ · Cornelius Faber¹⁹ · Laura C. Bell²⁰ · Patrícia Figueiredo^{21,22} · Joan C. Vilanova²³ · Francesco Santini^{24,25} · Ralf Mekte²⁶ · Sonia Waiczies^{13,15}

Received: 21 April 2024 / Revised: 26 April 2024 / Accepted: 30 April 2024 / Published online: 12 June 2024
© The Author(s) 2024

Introduction

The realm of MR intervention and theranostics is experiencing a rapid evolution. Within the broader scope of theranostics, paradigm shifts in non-invasive and invasive therapeutic intervention signify an era where treatment efficacy can be accurately tracked and assessed. The word Theranostics is a fusion of therapy and diagnostics, reflecting its dual purpose of treating and diagnosing diseases. It epitomizes a paradigm where treatment efficacy can be systematically monitored and optimized. Initially rooted in nuclear medicine with applications in diagnosing and treating cancer, it has undergone a transformative journey. Today, it encompasses a broader spectrum of imaging modalities, with MRI emerging as a non-invasive, patient-friendly, and potent clinical tool, alongside advancements in nanotechnology [1]. Far from being merely a trendy term, theranostics embodies a long-standing aspiration among scientists and clinicians to enhance patient care and advance personalized medicine. While some may view it as a buzzword [2] perhaps for securing research funding or driving healthcare policies, its essence lies in its potential to revolutionize healthcare delivery and outcomes. This evolution underscores the pivotal role of theranostics in pushing the boundaries of (molecular) imaging technologies to revolutionize patient care. Interventional MRI also has a rich history dating back to soon after the introduction of clinical diagnostic MRI [3]. Recognizing the superior soft tissue contrast capabilities of MRI, radiologists began exploring its use for guidance during interventional procedures, especially those involving head and neck lesions. Interventional MRI is a specialized domain where medical images do not only serve diagnostic purposes but also guide minimally invasive surgical or

vascular procedures. Procedures including those involving small incisions in the body, are aimed at diagnosing, treating, and even curing various conditions. Today, it is widely employed to guide various invasive and noninvasive diagnostic and therapeutic interventions, such as robotic in-bore-targeted biopsies [4] and has immense theranostic potential, such as in deep brain stimulation [5].

As part of the program of the upcoming 2024 Annual Meeting of the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB), the Congress Planning Committee has invited speakers from across Europe, experts in the field of MR theranostics and intervention, who will deliver plenary and educational talks in these corresponding fields.

Content

The ESMRMB program divides the focus topic on MR theranostics and intervention into 4 main sessions: (1) Multimodal imaging for theranostics, (2) Invasive interventional MR, (3) Noninvasive interventional MR and (4) The role of MRI in drug development.

The plenary will delve into recent advances and prospects in theranostics, covering the synthesis, delivery, and application of new probes, designed with identifiable markers for precise drug localization within the body. Among preclinical molecular imaging methods, fluorine (¹⁹F) MRI has gained prominence [6], with background-free detection making fluorine-containing molecules ideal tracers for various MRI applications, including quantification of inflammatory disorders [7, 8] and treatment assessment [9, 10]. However, the low in vivo availability of administered fluorinated materials limits sensitive reporting. Nonetheless, innovations in ¹⁹F tracer design enable precise imaging of specific cell types

Extended author information available on the last page of the article

[11] and measurement of physiologically important parameters like local oxygenation. Multi-targeted ^{19}F nanotracers, equipped with binding molecules targeting specific immune cell subtypes, enable comprehensive mapping of immune response dynamics by whole-body MRI [8]. Conjugating immunomodulating drugs to these nanotracers allows their use as theranostic tools for modulating specific immune cell functions. Synthesizing therapeutic agents containing both active constituents and markers for *in vivo* visualization within the target organ remains a key challenge in ^{19}F MRI theranostics [12]. This challenge can be addressed by utilizing iron-based nanoparticles or specific Gadolinium (Gd) or Manganese (Mn) complexes [13, 14]. A notable example of theranostics is molecular and cell therapy in the treatment of diabetes [15, 16]. In the clinical setting, confirmatory labeling and distinctions between transplanted cells and nanoparticles will ensure specific detection of therapeutic cells [17, 18]. Overall, this plenary session will underscore the transformative potential of MR theranostics and molecular imaging.

The first educational session is on multimodal imaging for theranostics and will give an update on established and emerging imaging and spectroscopic modalities in theranostics. Starting with methods in nuclear medicine, the nuclear theranostic approach aims to customize the management of various human diseases, improve patient selection, and enhance prognosis, while avoiding futile and costly diagnostic and therapeutic activities [19]. The aim is to engage a given target in dysfunctional cells or tissues. Although nuclear theranostics has primarily focused on oncology, significant novel applications are rapidly gaining traction in cardiology and neurology [20, 21]. The recent development of new radionuclide-based therapies has re-energized the field of targeted-radiotherapy [22]. Concomitantly, there is a growing recognition that theranostics can serve as convenient drug delivery systems, making theranostic strategies particularly appealing to large pharmaceutical companies seeking to develop more selective and efficient therapies [23]. The modality of MR spectroscopy (MRS) is instrumental in non-invasively elucidating tumor metabolism, particularly in adult-type diffuse gliomas, and is proving indispensable in theranostic approaches for timely diagnosis and treatment. Prognosis in adult-type gliomas pivots on mutations in isocitrate dehydrogenase (IDH) and chromosome 1p/19q codeletion [24]. Mescher–Garwood point-resolved spectroscopy (MEGA-PRESS) enables the simultaneous detection of 2-hydroxyglutarate (2HG)—a direct, downstream marker of IDH mutation [25]—and cystathionine, which accumulates preferentially in 1p/19q-codeleted gliomas [26], as demonstrated in both research and clinical settings [27]. These studies highlight the high specificity of MEGA-PRESS for both predictors in mutated gliomas, underscoring the importance of understanding the neurochemical profile

for early diagnosis, compared to current standard diagnostic classifications [24]. Rapid, accurate, and noninvasive prognosis stratification of diffuse glioma with edited MRS will be essential to expedite routine workup for patients with diffuse gliomas, thereby facilitating access to IDH inhibitor treatment. Hyperpolarization methods offer an unprecedented boost in MR sensitivity via non-destructive manipulation of quantum spin state populations (typically of ^{13}C & ^1H). This provides a unique promise for *in-vivo* drug spatial localization [28] and metabolic probing [29]. Target nuclei can be incorporated into drug molecules as motifs or molecular tags. Hyperpolarization methods include dynamic nuclear polarization (DNP) [30], parahydrogen-induced polarization (PHIP) [31] and signal amplification by reversible exchange (SABRE) [32]. Following hyperpolarization, drug distribution and metabolism can be tracked via MRS(I) methods. The enhanced signal persists for a limited time; therefore, the implementation of cutting-edge, rapid MR methodologies and chemical manipulation for long magnetic lifetimes is imperative. Mass spectrometry adds a powerful approach for studying drug spatial localization. Additionally, MR hardware can be manipulated for targeted magnetic delivery to increase the efficacy of therapeutics [33, 34] and complement the diagnostic potential of the discussed approaches.

The second educational session will focus on invasive interventional MRI methods as theranostic tools, highlighting MRI's versatility for needle-based therapeutic interventions [35, 36]. Thermoablation treatments including laser-induced interstitial laser therapy (LITT), radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA), established for coagulating various tumors, notably in the brain, liver, kidney, and prostate. While these procedures are typically monitored using CT or ultrasound, MR imaging offers real-time temperature monitoring through MR-thermometry, enhancing therapy precision. However, challenges like breathing or residual bleeding-induced artifacts on MR-thermometry persist. Technological advances, including lower field strength MR units, aim to enhance the utility of MR-guided needle-based interventions for treatments. MRI guidance is crucial for planning treatments in vital organs like the liver, breast, and prostate, aiding in biopsy, dosimetry, and improving outcomes [37, 38]. In liver interventions, MRI even enables intraprocedural dosimetry during tumor radioembolization [39]. Leveraging interventional MRI offers distinct advantages, including real-time imaging guidance, enhanced accuracy, and improved patient outcomes. Brain surgery is another aspect that benefits interventional MRI. Intraoperative MRI-guided brain surgery enhances effective and safe tumor resection [40, 41], and the treatment of epilepsy [42]. Recent advances include MRI-guided focused ultrasound for treating tremors in parkinsonism. This innovative technique enables precise targeting and real-time thermal monitoring

using MR thermometry [43]. Despite its benefits in neurosurgery, intraoperative MRI remains limited due to safety concerns. Strict safety protocols and personnel training are crucial to prevent accidents [44].

The third educational session will be non-invasive interventional MRI methods as theranostic tools. MR-guided high-intensity focused ultrasound (MR-HIFU) is an interventional treatment using HIFU that is guided by MRI for spatial treatment planning as well as monitoring of tissue heating or treatment effects. Ultrasound waves can be focused deep within a patient's body. Within the focus region, energy dissipation leads either to heating or to a mechanical disruption of tissue and cellular structures, depending on the wave intensity and the exact pulse sequence [45–47]. HIFU uses continuous sonications to thermally ablate tissue or induce local hyperthermia [48]. Besides offering soft tissue contrast, MRI is used to monitor near-real-time temperature mapping for feedback to the HIFU transducer. This ensures a defined thermal dose for tissue ablation and constant temperatures during hyperthermia treatments. Current clinically approved MR-HIFU applications are based on thermal tissue ablation, for the treatment of uterine fibroids, desmoid tumors, or painful bone diseases. A new clinical application is histotripsy which is induced by pulsed HIFU and involves mechanical ablation of tissue without significant heat deposition [45]. For this, other MR contrast mechanisms that monitor non-thermal tissue degradation provide feedback during therapy. The concepts of MR-HIFU will be reviewed with examples of current clinical applications and ongoing trials, also focusing on the translation of preclinical work. The potential application of histotripsy in oncology will be discussed. ThermalMR combines diagnostic MRI with targeted local thermal therapy using radiofrequency (RF) applicators in an integrated system [49]. Fighting fire with fire, hyperthermia is an adjunct treatment to enhance the efficacy of other anti-cancer treatments: chemotherapy, radiotherapy and immunotherapy [50] and has clinical potential in targeted drug delivery using thermo-responsive nano-carriers [51]. ThermalMR uses RF antenna arrays to selectively increase the temperature of a target region and is governed by RF features such as the frequency and geometry of phased arrays [52, 53]. The objective is to ensure uniform magnetic transmission fields for MRI and MR thermometry and facilitate targeted control of electric fields for thermal therapy. There will be a focus on ThermalMR as it explores temperature's role in biology and disease, introducing thermal cancer phenotyping, to advance thermal theranostics [54]. MRI-guided radiation therapy (MRgRT) represents an unprecedented therapeutic advantage compared to X-ray-based radiotherapy delivery systems by leveraging real-time imaging to customize treatments to each patient's tumor anatomy, ensuring precise targeting while sparing radiation exposure to surrounding healthy tissues

[55]. This transformative technology brings about a paradigm shift in the workflow of radiation oncology, demanding enhanced coordination among multidisciplinary teams to ensure precise treatment delivery. Upon implementation, it opens avenues for novel applications in radiation therapy, enabling the safe delivery of higher doses with enhanced preservation of healthy tissues, ultimately optimizing patient outcomes. The technical intricacies of advanced linear accelerators capable of delivering MRgRT will be outlined, along with a comprehensive summary of published experiences to date, emphasizing oncological outcomes and highlighting forthcoming challenges. MRI-guided neuromodulation is another interventional MRI that shows significant promise in neurological disorders [56, 57]. It includes techniques such as transcranial magnetic stimulation (TMS) and transcranial direct/alternate current stimulation (tDCS/tACS). Structural MRI is essential for modelling electric fields, while concurrent measurements with functional MRI (fMRI) and/or electroencephalography (EEG) are increasingly attracting more interest. Additionally, leveraging further multimodal imaging, including diffusion MRI (dMRI), holds the potential for more accurate targeting through the use of structural connectivity, based on real-time tractography [58]. Emphasis will be made on the integration of technologies as this not only refines therapeutic interventions but also deepens our understanding towards diagnostics, paving the way for more precise and personalized treatments particularly for psychiatric disorders.

The fourth educational session will be on the role of MRI in drug development and will focus on perspectives from academia and industry. Particularly in industry, positron emission tomography (PET) remains the major player during the drug discovery and development process, and during preclinical and clinical trials [59]. The use of hybrid PET-MRI enhances pharmacokinetics and pharmacodynamics, by offering simultaneous structural, microstructural, and functional information. In rare diseases, comprehensive PET-MR protocols are crucial for acquiring multimodal information on structural and functional tissue integrity. Identifying disease biomarkers and treatment responses requires careful consideration of hardware and software factors, such as radiotracer selection, MR acquisition protocols, QC procedures that ensure robust acquisitions and post-processing reproducibility to estimate disease-related and treatment-response-related metrics. Next attention will be paid to the contribution of preclinical MRI to drug development. Non-invasive imaging of whole organisms provides invaluable insights into physiology and pathology, including immune responses, surpassing what can be achieved through cell culture or organoid experiments. In vivo MRI provides dynamic, real-time data, unlike postmortem tissue analysis, which offers only a snapshot at a single time point. MRI stands out among non-invasive imaging methods due

to its ability to provide a multi-parametric view, enabling the assessment of various physiological and metabolic parameters. These parameters inform on toxicity, biodistribution, efficacy, mode of action, immune response, and potential adverse effects. Despite recent advances in sensitivity and specificity, the role of preclinical MRI in drug development has evolved rather than dramatically changed in the past two decades [60, 61]. Nonetheless, preclinical MRI remains essential for adhering to the 3R principle in drug development [62]. Advancing MRI biomarkers in drug development is crucial [63, 64]. MRI can influence various stages, from preclinical to clinical trials. During the preclinical stage, MRI reveals disease mechanisms, aiding target and drug validation. Early on, it assesses pharmacokinetics and tissue distribution for safety. In clinical trials, MRI biomarkers quantify treatment efficacy and safety, expediting decision timelines when determined as early, sensitive gauges of disease progression. However, challenges persist: MRI methods must be sensitive and specific to the disease progression or treatment response; integrated with other clinical data early on to provide a more comprehensive overview [65]. Quantitative measures are essential for precise monitoring [66], requiring reproducible imaging protocols. Regulatory approval is needed for MRI as a surrogate endpoint or companion diagnostic. Finally, MRI must be cost-effective and widely accessible for widespread use.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest All other authors do not report any potential conflict of interest.

Ethical approval J.J.F. reports grants from Siemens Healthineers outside the submitted work, F.C. has received honoraria from Janssen, Astellas, IPSEN, Recordati, Boston Scientific, AstraZeneca and Bayer for participation in expert committees and conferences, L.C.B. is an employee and stockholder at Genentech, Inc., and S.W. has received research funding from Novartis and Sanofi.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Zhang Z et al (2022) Theranostics for MRI-guided therapy: recent developments. *VIEW* 3(3):20200134
- Weber WA et al (2023) What is theranostics? *J Nucl Med* 64(5):669–670
- Thompson SM et al (2021) Body interventional MRI for diagnostic and interventional radiologists: current practice and future prospects. *Radiographics* 41(6):1785–1801
- Vilanova JC et al (2020) Robotic-assisted transrectal MRI-guided biops. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience. *Abdom Radiol* 45(12):4150–4159
- Aviles-Olmos I et al (2014) Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. *J Neurol Neurosurg Psychiatry* 85(12):1419–1425
- Maxouri O et al (2023) How to 19F MRI: applications, technique, and getting started. *BJR Open* 5(1):20230019
- Temme S et al (2015) Noninvasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions. *Circulation* 131(16):1405–1414
- Flögel U et al (2021) Multi-targeted 1H/19F MRI unmasks specific danger patterns for emerging cardiovascular disorders. *Nat Commun* 12(1):5847
- Flögel U et al (2012) Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. *Sci Transl Med* 4(146):146ra108
- Flögel U et al (2008) In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. *Circulation* 118(2):140–148
- Bouvain P et al (2023) Non-invasive mapping of systemic neutrophil dynamics upon cardiovascular injury. *Nat Cardiovasc Res* 2(2):126–143
- Starke L et al (2023) First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod. *Theranostics* 13(4):1217–1234
- Ding M, Liu W, Gref R (2022) Nanoscale MOFs: from synthesis to drug delivery and theranostics applications. *Adv Drug Deliv Rev* 190:114496
- Frantellizzi V et al (2020) New frontiers in molecular imaging with superparamagnetic iron oxide nanoparticles (SPIONs): efficacy, toxicity, and future applications. *Nucl Med Mol Imaging* 54(2):65–80
- Arifin DR, Bulte JWM (2021) In vivo imaging of pancreatic islet grafts in diabetes treatment. *Front Endocrinol (Lausanne)* 12:640117
- Saudek F et al (2010) Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. *Transplantation* 90(12):1602–1606
- Berkova Z et al (2008) Labeling of pancreatic islets with iron oxide nanoparticles for in vivo detection with magnetic resonance. *Transplantation* 85(1):155–159
- Waiczies S, Niendorf T, Lombardi G (2017) Labeling of cell therapies: How can we get it right? *Oncoimmunology* 6:e1345403
- Gomes Marin JF et al (2020) Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. *Radiographics* 40(6):1715–1740
- Scarborough J et al (2020) Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal

- immune activation model of neurodevelopmental disorders. *Brain Behav Immun* 88:461–470
21. Pala R et al (2021) Nanomaterials as novel cardiovascular therapeutics. *Pharmaceutics* 13(3):348
 22. Simó C et al (2024) Urease-powered nanobots for radionuclide bladder cancer therapy. *Nat Nanotechnol* 19:554–564
 23. Hapuarachchige S, Artemov D (2020) Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. *Front Oncol*. <https://doi.org/10.3389/fonc.2020.01131>
 24. Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol* 23(8):1231–1251
 25. Dang L et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 462(7274):739–744
 26. Branzoli F et al (2019) Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. *Neuro Oncol* 21(6):765–774
 27. Branzoli F, Marjanska M (2020) Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile. *Curr Opin Neurol* 33(4):413–421
 28. Fear EJ et al (2022) SABRE hyperpolarized anticancer agents for use in 1H MRI. *Magn Reson Med* 88(1):11–27
 29. van Zijl PCM et al (2021) Hyperpolarized MRI, functional MRI, MR spectroscopy and CEST to provide metabolic information in vivo. *Curr Opin Chem Biol* 63:209–218
 30. Ardenkjaer-Larsen JH et al (2003) Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. *Proc Natl Acad Sci U S A* 100(18):10158–10163
 31. Bowers CR, Weitekamp DP (1987) Parahydrogen and synthesis allow dramatically enhanced nuclear alignment. *J Am Chem Soc* 109(18):5541–5542
 32. Adams RW et al (2009) Reversible interactions with para-hydrogen enhance NMR sensitivity by polarization transfer. *Science* 323(5922):1708–1711
 33. Riegler J et al (2010) Targeted magnetic delivery and tracking of cells using a magnetic resonance imaging system. *Biomaterials* 31(20):5366–5371
 34. Muthana M et al (2015) Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. *Nat Commun* 6(1):8009
 35. Barkhausen J et al (2017) White paper: interventional MRI: current status and potential for development considering economic perspectives, part 1: general application. *Rofo* 189(7):611–623
 36. Barkhausen J et al (2017) White paper: interventional MRI: current status and potential for development considering economic perspectives, part 2: liver and other applications in oncology. *Rofo* 189(11):1047–1054
 37. van Luijtelea A, Futterer JJ, Bomers JG (2022) Minimally invasive magnetic resonance image-guided prostate interventions. *Br J Radiol* 95(1131):20210698
 38. Wimper Y, Futterer JJ, Bomers JGR (2022) MR imaging in real time guiding of therapies in prostate cancer. *Life (Basel)* 12(2):302
 39. Roosen J et al (2022) Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. *Eur J Nucl Med Mol Imaging* 49(13):4705–4715
 40. Rogers CM, Jones PS, Weinberg JS (2021) Intraoperative MRI for brain tumors. *J Neurooncol* 151(3):479–490
 41. Wach J et al (2021) Intraoperative MRI-guided resection in pediatric brain tumor surgery: a meta-analysis of extent of resection and safety outcomes. *J Neurol Surg A Cent Eur Neurosurg* 82(1):64–74
 42. Eid H et al (2020) Eight-year experience with 3-T intraoperative MRI integration in focal pediatric epilepsy surgery: impact on extent of resection, residual volumes, and seizure outcomes. *AJR Am J Roentgenol* 214(6):1343–1351
 43. Na YC et al (2015) Unilateral magnetic resonance-guided focused ultrasound pallidotomy for Parkinson disease. *Neurology* 85(6):549–551
 44. Rahmathulla G et al (2012) Surgical briefings, checklists, and the creation of an environment of safety in the neurosurgical intraoperative magnetic resonance imaging suite. *Neurosurg Focus* 33(5):E12
 45. Khokhlova VA et al (2015) Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. *Int J Hyperthermia* 31(2):145–162
 46. Siedek F et al (2019) Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU): technical background and overview of current clinical applications (part 1). *Rofo* 191(6):522–530
 47. Siedek F et al (2019) Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU): overview of emerging applications (part 2). *Rofo* 191(6):531–539
 48. Sebeke LC et al (2021) Visualization of thermal washout due to spatiotemporally heterogenous perfusion in the application of a model-based control algorithm for MR-HIFU mediated hyperthermia. *Int J Hyperthermia* 38(1):1174–1187
 49. Winter L et al (2015) Thermal magnetic resonance: physics considerations and electromagnetic field simulations up to 23.5 Tesla (1GHz). *Radiat Oncol* 10:201
 50. Tittsworth WL et al (2014) Fighting fire with fire: the revival of thermotherapy for gliomas. *Anticancer Res* 34(2):565
 51. Ji Y et al (2020) Controlled release of therapeutics from thermoresponsive nanogels: a thermal magnetic resonance feasibility study. *Cancers* 12(6):1380
 52. Saha N et al (2023) Advanced radio frequency applicators for thermal magnetic resonance therapeutics of brain tumors. *Cancers* 15(8):2303
 53. Oberacker E et al (2021) Patient-specific planning for thermal magnetic resonance of glioblastoma multiforme. *Cancers* 13(8):1867
 54. Brito B et al (2021) Smart magnetic resonance imaging-based therapeutics for cancer. *Theranostics* 11(18):8706–8737
 55. Ocanto A et al (2024) MR-LINAC, a new partner in radiation oncology: current landscape. *Cancers* 16(2):270
 56. Esmailpour Z et al (2020) Methodology for tDCS integration with fMRI. *Hum Brain Mapp* 41(7):1950–1967
 57. Bergmann TO et al (2021) Concurrent TMS-fMRI for causal network perturbation and proof of target engagement. *Neuroimage* 237:118093
 58. Aydogan DB et al (2023) Real-time tractography-assisted neuro-navigation for TMS. *bioRxiv*. <https://doi.org/10.1101/2023.03.09.531565>
 59. Nerella SG et al (2022) PET molecular imaging in drug development: the imaging and chemistry perspective. *Front Med*. <https://doi.org/10.3389/fmed.2022.812270>
 60. Beckmann N et al (2004) Magnetic resonance imaging in drug discovery: lessons from disease areas. *Drug Discov Today* 9(1):35–42
 61. Kaggie JD et al (2017) Role of magnetic resonance in drug development. In: Webb GA (ed) *Modern magnetic resonance*. Springer International Publishing, Cham, pp 1–20
 62. Wachsmuth L et al (2021) Contribution of preclinical MRI to responsible animal research: living up to the 3R principle. *Magn Reson Mater Phys* 34(4):469–474
 63. O'Connor JPB et al (2017) Imaging biomarker roadmap for cancer studies. *Nat Rev Clin Oncol* 14(3):169–186
 64. Selby NM et al (2018) Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European

- cooperation in science and technology action PARENCHIMA. *Nephrol Dial Transplant* 33(suppl_2):ii4–ii14
65. Littlejohns TJ et al (2020) The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. *Nat Commun* 11(1):2624
66. Weingartner S et al (2022) Development, validation, qualification, and dissemination of quantitative MR methods: Overview and

recommendations by the ISMRM quantitative MR study group. *Magn Reson Med* 87(3):1184–1206

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Milan Hájek¹ · Ulrich Flögel² · Adriana A. S. Tavares³ · Lucia Nichelli^{4,5} · Aneurin Kennerley^{6,7} · Thomas Kahn⁸ · Jurgen J. Futterer⁹ · Aikaterini Firsiori¹⁰ · Holger Grull^{11,12} · Nandita Saha^{13,14} · Felipe Couñago¹⁶ · Dogu Baran Aydogan¹⁷ · Maria Eugenia Caligiuri¹⁸ · Cornelius Faber¹⁹ · Laura C. Bell²⁰ · Patrícia Figueiredo^{21,22} · Joan C. Vilanova²³ · Francesco Santini^{24,25} · Ralf Mekle²⁶ · Sonia Waiczies^{13,15}

✉ Sonia Waiczies
Sonia.Waiczies@mdc-berlin.de

- ¹ Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- ² Experimental Cardiovascular Imaging, Institute for Molecular Cardiology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ³ Centre for Cardiovascular Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK
- ⁴ Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute, ICM, Paris, France
- ⁵ Department of Neuroradiology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
- ⁶ Department of Sports and Exercise Science, Institute of Sport, Manchester Metropolitan University, Manchester, UK
- ⁷ Department of Biology, University of York, York, UK
- ⁸ Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany
- ⁹ Minimally Invasive Image-Guided Intervention Center (MAGIC), Department of Medical Imaging, Radboudumc, Nijmegen, The Netherlands
- ¹⁰ Unit of Diagnostic and Interventional Neuroradiology, Diagnostic Department, University Hospitals of Geneva, Geneva, Switzerland
- ¹¹ Institute of Diagnostic and Interventional Radiology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
- ¹² Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany

- ¹³ Max-Delbrück-Centrum Für Molekulare Medizin (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany
- ¹⁴ Charité-Universitätsmedizin Berlin, Berlin, Germany
- ¹⁵ Experimental and Clinical Research Center (ECRC), A Joint Cooperation Between the Charité Medical Faculty and the MDC, Berlin, Germany
- ¹⁶ Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain
- ¹⁷ A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
- ¹⁸ Neuroscience Research Center, Department of Medical and Surgical Sciences, Università Degli Studi “Magna Graecia”, Catanzaro, Italy
- ¹⁹ Translational Research Imaging Center (TRIC), Clinic of Radiology, University of Münster, Münster, Germany
- ²⁰ Early Clinical Development, Genentech Inc., South San Francisco, USA
- ²¹ Institute for Systems and Robotics, ISR-Lisboa, Lisbon, Portugal
- ²² Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
- ²³ Department of Radiology, Clínica Girona, Institute of Diagnostic Imaging (IDI) Girona, University of Girona, 17004 Girona, Spain
- ²⁴ Department of Radiology, University Hospital of Basel, Basel, Switzerland
- ²⁵ Basel Muscle MRI, Department of Biomedical Engineering, University of Basel, Basel, Switzerland
- ²⁶ Center for Stroke Research Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany